Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479700 | 0.88 | SCN9A (0.46) | HRH4SCN9AKCNH2 | |
| SCHEMBL3223902 | 0.88 | SCN9A (0.46) | HRH4SLC6A2SLC6A4SCN9ASLC6A3 | |
| SCHEMBL3479616 | 0.86 | SCN9A (0.44) | HRH4SCN9AKCNH2DRD2DRD3 | |
| SCHEMBL3226036 | 0.85 | SLC6A2 (0.43) | HRH4SLC6A2SLC6A4SCN9ASLC6A3 | |
| SCHEMBL3230914 | 0.84 | SCN9A (0.45) | HRH4SCN9ACYP2C9 | |
| SCHEMBL3479598 | 0.84 | HTR3A (0.46) | HRH4SLC6A2SLC6A4SCN9ASLC6A3 | |
| SCHEMBL3479576 | 0.84 | SCN9A (0.44) | SLC6A2SCN9AKCNH2 | |
| SCHEMBL3480219 | 0.84 | HRH4 (0.43) | HRH4SCN9AKCNH2CYP2D6CYP2C19 | |
| SCHEMBL3232247 | 0.84 | SCN9A (0.48) | HRH4SCN9ADRD2DRD3 | |
| SCHEMBL3232074 | 0.84 | CYP11B2 (0.45) | SLC6A2SLC6A4SCN9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA1B, ADRB1, ADRA1D | HRH4 90/4885SLC6A2 28/4885SLC6A4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.